Drug Discovery Today Volume 23, Number 3 March 2018 PERSPECTIVE feature Is preclinical data sharing the new norm? Katharine A. Briggs Is preclinical data sharing the new norm? In my experience, it is certainly becoming more commonplace. However, it is not yet standard practice and remains the preserve of special projects. Here, I expound the beneﬁts of sharing proprietary preclinical data using examples of successful initiatives. The main barriers to data sharing are then described, with suggestions for how these might be overcome. To maximise the beneﬁts and minimise the risks involved, I suggest that organisations look to develop standard operating procedures for data sharing. Introduction Reasons for data sharing health research and aims to increase the avail- In this article, I look at the beneﬁts and risks Beneﬁts to public health ability and use of health research data in ways associated with sharing preclinical data. The Approximately 35% of all drug development that are equitable, ethical, and efﬁcient (http:// projects fail as a result of toxicity detected during proprietary nature of these data means that grants.nih.gov/grants/policy/data_sharing/; preclinical safety studies . Therefore, animal initiatives to share these data tend to be restricted www.mrc.ac.uk/research/research-policy-ethics/ studies are an important safeguard for
Drug Discovery Today – Elsevier
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera